Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nano antibody capable of being combined with human CD38 and application thereof

A monoclonal antibody, sequence technology, applied in the field of biomedicine

Active Publication Date: 2020-10-23
Y CLONE MEDICAL SCI CO LTD
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In July 2019, Johnson & Johnson’s world’s first CD38 monoclonal antibody, Daratumumab Injection, was launched in China for the monotherapy of adult patients with relapsed and refractory mul

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nano antibody capable of being combined with human CD38 and application thereof
  • Nano antibody capable of being combined with human CD38 and application thereof
  • Nano antibody capable of being combined with human CD38 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0072] 1. Preparation of Immunogen

[0073] Based on the CD38 protein sequence and gene sequence information on the NCBI website, we analyzed and designed a polypeptide sCD38 that can effectively induce alpacas to produce specific antibodies against the extracellular domain of CD38, and linked His-tag (sCD38-his) or rabbit Fc (sCD38-rFc) was used for subsequent purification and detection.

[0074] 2. Alpaca immunity and antiserum acquisition

[0075] The alpaca was primed with an emulsified mixture of 250 μg sCD38-rFc protein and 250 μl Freund’s complete adjuvant, and boosted three times with sCD38-rFc protein and 250 μl Freund’s incomplete adjuvant on the 14th day, 28th day, and 42th day 1 week after the second and third immunizations, blood was collected to detect the antiserum titer; 1 week after the fourth immunization, 100 ml of blood was collected for the construction of the phage antibody library.

[0076] The antiserum titer was detected by ELISA, and the detection p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a polypeptide capable of being combined with human CD38. The polypeptide comprises three complementary determining regions CDR1-3, the CDR1 sequence is one of or comprises sequences shown in SEQ ID NO:1-36, the CDR2 sequence is one of or comprises sequences shown in SEQ ID NO:37-72, and the CDR3 sequence is one of or comprises sequences shown in SEQ ID NO:73-111. Accordingto the invention, nano antibody drug development and diagnostic reagent research and development are carried out on hematopoietic malignant tumors. By preparing CD38 protein and immunizing alpaca andby a platform technology for displaying a nano monoclonal antibody by utilizing a phage library and the like, the invention screens a nano antibody VHH which is specifically combined with CD38, identifies a CDR sequence of the antibody, and constructs a humanized antibody C38NB; and meanwhile, the curative effect of the C38NB in treating multiple myeloma is evaluated in vivo by utilizing a humanized mouse model. The invention provides a potential nano-antibody new drug and a cell therapy new drug for clinical treatment of hematopoietic malignant tumors, and also provides a corresponding detection reagent for diagnosis of hematopoietic malignant tumors.

Description

technical field [0001] The invention relates to the field of biomedicine. More particularly, it relates to a polypeptide that can bind to human CD38, and the application of the polypeptide in the preparation of CD38 detection agent or hematopoietic malignant tumor treatment drug. Background technique [0002] CD38, also known as cyclic ADP ribose hydrolase, is a transmembrane glycoprotein. CD38 is expressed very low on normal lymphocytes and myeloid cells, as well as some tissues of non-hematopoietic origin, while upregulation is found in many hematopoietic malignancies (such as multiple myeloma cells) and cell lines derived from hematopoietic malignancies . Therefore, for such CD38-positive tumor conditions, anti-CD38 antibodies can be used as detection agents or therapeutic agents. [0003] In general, anti-CD38 monoclonal antibodies can clear tumor cells with high expression of CD38 through antigen-antibody immune response mechanism, the main mechanism is through 1) di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/40C07K16/00C12N15/13G01N33/574G01N33/577A61K39/395A61P35/00
CPCC07K16/2896C07K16/40C07K16/005G01N33/57407G01N33/57492G01N33/577A61P35/00C07K2317/22C07K2317/24C07K2317/565C07K2317/567C07K2317/569C07K2317/92G01N2333/70596A61K2039/505
Inventor 吴稚伟吴喜林黄碧莲
Owner Y CLONE MEDICAL SCI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com